A Single-centre, Randomised, Double-blind, Placebo-controlled, Multiple-dose Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Aug 2018
At a glance
- Drugs Semaglutide (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 08 Aug 2018 Status changed from active, no longer recruiting to completed.
- 11 Apr 2018 Planned End Date changed from 30 Jul 2018 to 14 Aug 2018.
- 11 Apr 2018 Status changed from recruiting to active, no longer recruiting.